The effect of DNMT inhibition (decitabine) on the sensitivity of RCC cell lines with proven hypermethylation to sunitinib suggests a possible connection of the PON1 methylation status to the sensitivity of RCC to sunitinib. Here, PON1 is linked to renal cell adenocarcinoma.